FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, particularly to endocrinology. For continuous monitoring of glycemia by means of a computing device, a target glycemic state is determined, including a target glycemia level and a target rate of change of the target glycemia level; determining the initial glycemic state including an initial glycemia level and an initial rate of change of the initial glycemia level, the initial glycemia state being different from the target glycemia state. By hazard analysis logic of the computing device, a return path for a transition from the initial glycemic state to the target glycemic state is calculated, the return path comprising at least one intermediate glycemic state associated with the transition from the initial glycemic state to the target glycemic state. Target return path is calculated by the hazard analysis logic based on a hypo- or hyperglycemia hazard associated with the at least one intermediate glycemic state of the target return path. By means of the computing device, human treatment is adjusted to transfer a person from the registered glycemic state to a target glycemic state based on the return path and / or hypo- or hyperglycemia hazard metric. At least one hazard metric associated with the registered glycemic state includes the total estimated time of the person's transition from the registered glycemic state to the target glycemic state via the return path, and the total estimated time is calculated based on the specified maximum acceleration of glycemia and the number of intermediate glycemic states on the return path.
EFFECT: group of inventions makes it possible to obtain hazard metrics associated with the results of measurements with continuous monitoring of glycemia taking into account the specified maximum acceleration of glycemia, which is adjusted based on the physiology of the patient and the number of intermediate glycemic states on the return path.
28 cl, 19 dwg
